PTO/SB/08B (08-03)

AUG 3 Q 2004 &

Sheet

## Substitute for form 1449B/PTO INFORMATION DISCESSES STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known					
Application Number 10/766,363					
Filing Date January 27, 2004					
First Named Inventor	Gregory, Richard				
Art Unit	Not yet assigned /636				
Examiner Name	Not yet assigned GUZO				
Attorney Docket Number	016930-005400US				

U.S. PATENT DOCUMENTS+						
		Document Number				
Examiner Initiats*	Cite No. <sup>1</sup>	Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
gi	AA	US-6,210,939	04-03-2001	Gregory et al.		
01	AB	US 6,290,949	09-18-2001	French et al.		
01	AC	US 6,333,030	12-25-2001	Curiel		
or	AD	US 6,503,501	01-17-2003	Anderson et al.		
o	AE	US-6,511,847 B1	01-28-2003	Zhang et al.		
07	AF	US 2003/0091534	05-15-2003	Gregory et al.		
ילי	AG	US 6,613,563	09-02-2003	Sosnowski et al.		

				FOREIGN PA	TENT DOCUME	NTS			
Examiner Initials*	Cite No. <sup>1</sup>	Fore	eign Patent Doc	ument Kind Code <sup>s</sup> ( <i>il known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, L Where Relevar Passages or Rele Figures Appea	nt vant	T <sup>©</sup>
سعق	AH	wo	94/24297		10-1994				
ı			NOI	N PATENT LIT	ERATURE DOC	UMENTS			
Examiner Initials *	Cite No.1			al, serial, symposiu		article (when appropriate) ate, page(s), volume-issu e published.		T²	
Je	AI		Aiello et al. Adenovirus 5 DNA Sequences Present and RNA Sequences Transcribed in Transformed Human Embryo Kidney Cells (HEK-Ad-5 or 293) Virology 94:460-469						
N	, AJ	Anderson, W. French, Nature, Vol. 392, pp. 25-30, 1998.							
o	AK	Aulitzky et al. "Recombinant Tumour Necrosis Factor Alpha Administered Subcutaneously or Intramuscularly for Treatment of Advanced Malignant Disease: a Phase I Trial." Eur. J. Cancer 27(4):462-467 (1991).					isease: a		
07	AL	Austin, E.A. and Huber, B.E. "A First Step in the Development of Gene Therapy for							
n	АМ	Bacchetti, S. and Graham, F. "Inhibition of cell proliferation by an adenovirus vector expressing the human wild type p53 protein." International Journal of Oncology 3:781-788 (1993).							
07	. AN	Baker et al. "Suppression of Human Colrectal Carcinoma Cell Growth by Wild-Type p53." 249:912-915 (1990).							
N	AO	Bartek et al. "Aberrant expression of the n53 anconvotein is a common feature of a wide							

Examiner Signature	David Jugo	Date Considered	2/5/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Papplicant is to place a check mark here if English language Translation is attached.

Substitute	for form 144	9B/PTO		Complete if Known
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/766,363
			riiing Dale	January 27, 2004
			First Named Inventor	Gregory, Richard
			Art Unit	Net-yet assigned / 6 3 C
(use as many sheets as necessary)		Examiner Name	Not yet assigned GUZO	
Sheet	4	of	Attorney Docket Number	016930-005400US

		FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document  Publication Date MM-DD-YYYY  Name of Patentee or Applicant of Cited Document  Pages, Columns, Lie Where Relevant Passages or Relevant Document  Pages, Columns, Lie Where Relevant Passages or Relevant Passages or Relevant Passages or Relevant Pages, Columns, Lie Where Relevant Passages or Relevant Pages, Columns, Lie Where Relevant Pages, C	ant 🚙				
sz	AP	Berkner, Kathleen L. and Sharp, Phillip A. "Effect of the tripartite leader on synthesis of a non-viral protein in an adenovirus 5 recombinant." Nucleic Acids Research 13(3):841-857 (1985).					
_\	AQ	Boshart et al. "A Very Strong Enhancer Is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus." Cell 41:521-530 (1985).					
	AR	Bressac et al. "Abnormal structure and expression of p53 gene in human hepatocellular carcinoma." Proc. Natl. Acad. Sci. (USA) 87:1973-1977 (1990).					
	AS	Buller et al., Cancer Gene Therapy, Vol. 9, pp. 553-566, 2002.					
	AT	Caruso et al. "Regression of established macroscopic liver metastases after in situ transfduction of a suicide gene." Proc. Natl. Acad. Sci. (USA) 90:7024-7028 (1993).					
	AU	Challberg, M.D. and Kelly, T.J. PNAS USA, 76:655-659 (1979).					
	AV	Casez et al., Oncogene, vol. 6(10), pp. 1791-1797, 1991.					
	AW	Chen et al. "Genetic Mechanisms of Tumor Suppression by the Human p53 Gene." Science 250:1576-1580 (1990).					
	AX	Chen et al. "Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate." Oncogene 6:1799-1805 (1991).					
	AY	Cheng et al. "Suppression of Acute Lymphoblastic Leukemia by the Human Wild-Type p53 Gene." Cancer Research 52:222-226 (1992)	•				
	AZ	Colby, W.W. and Shenk, T.J., "Adenovirus Type 5 Virions Can be Assembled in Vivo in the Absence of Detectable Polypeptide IX" Virology 39:977-980 (1981).					
	ВА	Culver et al. "In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors" Science 256:1550-1552 (1992).					
	BB	Culver et al. "Lymphocytes as a cellular vehicles for gene therapy in mouse and man."  Proc. Natl. Acad. Sci. USA 88:3155-3159 (1991).					
	ВС	Demetri et al. "A Phase I Trial of Recombinant Human Tumor Necrosis Factor and Interferon-Gamma: Effects of Combination Cytokine Administration In Vivo." J. Clin. Oncol. 7(10):1545-1553.					
oz	BD	Diller et al. "p53 Functions as a Cell Cycle Control Protein in Osteosarcomas." Mol. Cell. Biology 10:5772-5781 (1990).  El-Deiry et al. "WAF1, a Potential Mediator of p53 Tumor Suppression." Cell 75:817-825 (1993).					

Examiner Signature	David Luga	Date Considered	2/5/05

Substitute for form 14498/PTO INFORMATION DISCLOSURE				Complete if Known		
				Application Number	10/766,363	
				Filing Date	January 27, 2004	
STATEMENT BY APPLICANT			PLICANT	First Named Inventor	Gregory, Richard	
				Art Unit	Net yet assigned / 6 3 6	
(use as many sheets as necessary)		Examiner Name	Not yet assigned GUZO			
Sheet	5	of	<u>-</u>	Attorney Docket Number	016930-005400US	

		FOREIGN PA					
Examiner Cite No.1		Foreign Patent Document  Publication Date MM-DD-YYYY  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>4</sup> (Finner)  Name of Patentee or Applicant of Cited Passages or Figures Applicant of Cited Pages, Column Pages					
OL.	BE	Ezzidine et al. "Selective Killing of Gli Transfer of the Herpes Simplex Virus 7 3:608-614 (1991).					
	BF	Feinstein et al. "Expression of the norm Oncogene 7:1853-1857 (1992).	al p53 gene ind	uces differentiation o	f K562 cells."		
	BG	Freeman et al. "The "Bystander Effect" Mass Is Genetically Modified." Cancer			of the Tumor		
	ВН	Fox, Nature Biotechnology, Vol. 18, pp	o. 143-144, 2000	).			
	BI	"Gene Therapy Shows Promise for Figh	nting Cancer", A	ACS News Center, 8/2	21/00.		
	.B1	Ghosh-Choudhury et al. "Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of full length genomes." EMBO Journal 6:1733-1739 (1987).					
	вк	Gooding et al. "Molecular Mechanisms by Which Adenoviruses Counteract Antiviral Immune Defenses." Crit. Rev. Immunol. 10:53-71 (1990).					
	BL	Gomez-Navarro et al., European Journa	of Cancer, Vo	l. 35, No. 6, pp. 867-	885, 1999.		
	ВМ	Graham, F.L. and van der Eb, A.J. "A N Human Adenovirus 5 DNA." Virology	lew Technique 52:456-467 (19	for the Assay of Infect 73).	ctivity of		
	BN	Graham, F.L. and Prevec, L. Vaccines: New Approaches to Immunological Problems. R. W. Ellis (ed.), Boston: Butterworth-Heinemann, 363-390 (1992).					
	во	Gura, Science, Vol. 278, pp. 1041-1042	, 1997.				
	ВР	Haj-Ahmad and Graham, Development of a helper-independent human adenovirus vector and its use in the transfer of the herpes simplex virus thymidine kinase gene, J. Virol. 57(1): 267-274, Jan. 1986.					
	BQ	Heuvel et al. "Association between the cellular p53 and the adenovirus 5 E1B-55kd proteins reduces the oncogenicity of Ad-transformed cells." EMBO Journal 9:2621-2629 (1990).					
	BR	Hock et al. "Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon .gamma"  Proc. Natl. Acad. Sci. USA 90:2774-2778 (1992).					
or	BS	Hollstein et al. "p53 Mutations in Huma	ın Cancers." Sci	ence 253:49-53 (199	1).		

Considered

Signature

Substitute	for form 1449	B/PTO		Complete if Known
INFORMATION DISCLOSURE			Application Number	10/766,363
			riing Dale	January 27, 2004
STATEMENT BY APPLICANT		First Named Inventor	Gregory, Richard	
			Art Unit	Not yet assigned / 6 3 6
(use as many sheets as necessary)		Examiner Name	Not yet assigned GUZO	
Sheet	6	of	Attorney Docket Number	016930-005400US

			TENT DOCUME	NTS	·		
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>6</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Line Where Relevant Passages or Relevar Figures Appear		
02	ВТ	Horwitz, Marshall S. "Adenoviridae an New York: Raven Press, 1679-1721 (1		tion." sVirology B.N	. Fields (ed.),		
1	BU	Horvath, J. and Weber, J.M. "Nonperm to Adenovirus Type 2 Infection." J. Vi			Lymphocytes		
	BV	Huang et al. "A cellular protein that co retinoblastoma gene product." Nature 3			ing to the		
	BW	Huber et al. "Retroviral-mediated gene carcinoma: An innovative approach for 88:8039-8043 (1991).				. •	
	ВХ	Hunter, T. "Braking the Cycle." Cell 7	5:839-841 (1993	3).		-	
	BY	Jones, N. and Shenk, T. "Isolation of A Defective for Transformation of Rat Er				-	
	BZ	Kamb et al. "A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types." Science 264:436-440 (1994).					
	CA	Kuball et al., Journal of Clinical Oncol	ogy, Vol. 20, N	o. 4, pp. 957-965, 200	)2.		
	СВ	Kuerbitz et al. "Wild-type p53 is a cell irradiation." Proc. Natl. Acad. Sci. USA			ing		
	СС	Landmann et al. "Prolonged Interferongamma. Application by Subcutaneous Infusion in Cancer Patients: Differential Response of Serum CD14, Neopterin, and Monocyte HLA Class I and II Antigens." J. Interferon Res. 12(2):103-111 (1992).					
	CD	CD Lane, D.P. "p53, guardian of the genome." Nature 358:15-16 (1992).					
	CE	Lee et al. "Human Retinoblastoma Susa Sequence." Science 235:1394-1399 (19		: Cloning, Identificat	ion, and		
	CF	Lemaistre et al. "Therapeutic effects of in patient with chronic lymphocytic leu	kaemia." Lance	t 337:1124-1125 (19	91).		
J	CG	Lemarchand, Patricia. "Adenovirus-mediated transfer of a recombinant human .alphasub.1 -antitrypsin cDNA to human endothelial cells." Proc. Natl. Acad. Sci. USA 89:6482-6486 (1992).					
82	СН	Levine, A.J. "The Tumor Suppressor G	enes." Annu. R	ev. Biochem. 62:623-	651 (1993).		

Evaninas		Data	
Examiner Signature	D. D. m	Date Considered	
Signature	Vary	Considered	2/5/03

Substitute	for form 144	B/PTO		Complete if Known
INIEO	DASATI	ON DISCLOSUE:	Application Number	10/766,363
		ON DISCLOSUR	1 FILING Date	January 27, 2004
STAT	FMFN	T BY APPLICAN	First Named Inventor	Gregory, Richard
			Art Unit	Not yet assigned / 636
(	use as man	y sheets as necessary)	Examiner Name	Not yet assigned (7020
Sheet	7	of	Attorney Docket Number	016930-005400US

		FOREIGN PA	TENT DOCUME	ENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document  Publication Date MM-DD-YYYY  Name of Patentee or Applicant of Cited Passages or Relev Passages or Relev Document  Pages, Columns, Li Where Relevant Passages or Relev Passages or Relev Figures Appear								
R	CI	Lowe et al. "p53 is required for radiation-induced apoptosis in mouse thymocytes." Nature 362:847-852 (1993).								
	cı	Lowe et al. "p53-Dependent Apoptosis Modulates the Cytotoxicity of Anticancer Agents." Cell 74:957-967 (1993).								
	СК	Marshall, Science, Vol. 299, p. 320, 2003.								
	CL	conditionally expresses human wild-ty (1990).	Mercer, et al. "Negative growth regulation in a glioblastoma tumor cell ine that conditionally expresses human wild-type p53." Proc. Natl. Acad. Sci. USA 87:6166-6170 (1990)							
	СМ	Metzger, Gerard and Werbin, Harold. Induced Covalent-like Binding of Som Biochemistry 18(4):655-659 (1979).	e Nonhistone Pr	roteins to DNA in Chi	romatin."					
	CN	Moolten, F.C. "Tumor Chemosensitivity Conferred by Inserted Herpes Thymidine Kinase Genes: Paradigm for a Prospective Cancer Control Strategy." Cancer Res. 46:5276-5281 (1986).								
	со	Nakabayashi et al. "Transcriptional Regulation of .alphaFetoprotein Expression by Dexamethasone in Human Hepatoma Cells." The Journal of Biological Chemistry 264:266-271 (1989).								
	СР	Orkin et al. "Report and Recommendations of the Panel to Asses the NIH Investment in Research on Gene Therapy", Gene Therapy, 1995.								
	cq	Palmer et al. "Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes." Proc. Natl. Acad. Sci. USA 88:1330-1334 (1991).								
	CR	Rao et al. "The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins." Proc. Natl. Acad. Sci. USA 89:7742-7746 (1992).								
	cs	Ravoet et al. "Non-Surgical Treatment of Hepatocarcinoma." Journal of Surgical Oncology Supplement 3:104-111 (1993).								
	СТ	Rich et al. "Development and Analysis of Recombinant Adenoviruses for Gene Therapy of cystic Fibrosis." Human Gene Therapy 4:461-476 (1993).								
	CU	Rosenfeld et al. "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium." Cell 68:143-155 (1992).								
	cv	Ross et al., Human Gene Therapy, Vol. 7, pp. 1781-1790, 1996.								
r	cw	Sarnow et al. "Adenovirus E1b-58kd T Physically Associated with the Same 54 28:387-394 (1982).	umor Antigen ar 1 kd Cellular Pro	nd SV40 Large Tumo otein in Transformed	r Antigen Are Cells." Cell					
Examiner Signature		Davil Tugo	Date Considered	2/5/05						

Substitute	for form 1449B/PT	то		Complete if Known
INIEO		DICCL OCUDE	Application Number	10/766,363
		DISCLOSURE	Filing Date	January 27, 2004
STAT	EMENTE	BY APPLICANT	First Named Inventor	Gregory, Richard
			Art Unit	Not yet assigned /636
(	use as many sh	eets as necessary)	Examiner Name	Not yet assigned GUZO
Sheet	8	of	Attorney Docket Number	016930-005400US

		FOREIGN PA	TENT DOCUME	ENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>3</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Cotumns, Lines Where Relevant Passages or Relevant Figures Appear	i
or	сх	Shaw et al. "Induction of apoptosis by line." Proc. Natl. Acad. Sci. USA 89:44	wild-type p53 ii 195-4499 (1992	n a human colon tumo ).	or-derived cell	
1	CY	Siegfried, W. "Perspectives in Gene The Clin. Endocrinol. 101:7-11 (1993).	erapy with Rec	ombinant Adenovirus	es." Exp.	
·	CZ	Sorscher et al. "Tumor cell bystander k Escherichia coli DeoD gene to generate				
	DA	Spector, David J. "The Pattern of Integr 5-Transformed Human Cell Line 293."			e Adenovirus	
	DB	Stewart et al. "Difference imaging of acray crystallography and electron micros	scopy." EMBO	Journal 12:2589-2599	9 (1993).	
	DC	Smith, R.R. et al., "Studies of the use o cervix," Cancer 9(6):1211-1218 (1956)		treatment of carcinon	a of the	
	DD	Straus, S.E. "Adenovirus infections in I New York: Plenum Press, 451-496 (19		denoviruses. H.S. Gir	nsberg (ed.),	
	DE	Supersaxo et al. Pharm. Res. 5(8):472-	476 (1988).			
	DF	Takahashi et al. "p53: A Frequenct Tar Science 246:491-494 (1989).	get for Genetic	Abnormalities in Lun	g Cancer."	
	DG	Takahashi et al. "Wild-type but not Mu Cancer Cells Bearing Multiple Genetic				
	DH	Thimmappaya et al. "Adenovirus VAI mRNAs at Late Times after Infection."			ation of Viral	
	DI	Twersky, "Girl's Parents Plead for Gene	e Therapy to Re	sume", WebMD Heal	lth, 9/27/00.	_
	DJ	Verma et al., Nature, Vol. 389, pp. 239	-242, 1997.			
	DK	Wang et al. "Quantitation of mRNA by Sci. USA 86:9717-9721 (1989).	the polymerase	chain reaction." Proc	. Natl. Acad.	
	DL	Watanable et al. "Cell-specific Enhance alphaFetoprotein Gene." The Journal				
or	DM	Weiss et al., "Methods Faulted in Fatal 12/8/99.	Gene Therapy"	, Washington Post, pa	ige Al,	

Signature Dany Tuyo Considered 7/1/5	Examiner Signature	David Luzo	Date Considered	2/5/05
--------------------------------------	-----------------------	------------	--------------------	--------

Substitute	for form 1449	в/РТО		Complete if Known
INIEG		ON DICCI OCII	Application Number	10/766,363
		ON DISCLOSU	riing Dale	January 27, 2004
STAT	EMEN	T BY APPLICA	First Named Invent	or Gregory, Richard
			Art Unit	Not yet assigned / 6 3 6 .
(	use as man	y sheets as necessary)	Examiner Name	Not yet assigned GUZO
Sheet	9	of	Attorney Docket Nu	

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document  Publication Date MM-DD-YYYY  Name of Patentee or Applicant of Cited Document  Name of Patentee or Applicant of Cited Document  Passages or Relevant Passages or Relevant Figures Appear						
muais	NO.							
gi	DN	Wen et al., Cancer Gene Therapy, Vol. 10, pp. 224-238, 2003.						
01	DO	Programmed	White et al. "The 19-Kilodalton Adenovirus E1B Transforming Protein Inhibits Programmed Cell Death and Prevents Cytolysis by Tumor Necrosis Factor .alpha" Mol. Cell. Biol. 12:2570-2580 (1992).					
N	DP	Wills et al. Human Gene Therapy 5:1079-1088 (1994).						
or	DQ	Wills, K.N. et al., "Adenovirus vectors for gene therapy of cancer," Genetically Targeted Research & Therapeutics: Antisense & Gene Therapy Abstract S216, Apr. 12-18, 1993.						
27	DR	Winnacker, E.L., From Genes to Clones, pp. 342-343, VCH Publishers, New York, NY, 1987.						
N	DS	Yonish-Rouach et al. "Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6." Nature 352:345-347 (1991).						
ve	DT	Zhang, W.W. et al., "High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus," Canc. Gene Ther. 1(1):5-13 (1994).						

Examiner Signature	Dairl June	Date Considered	2/3/05
<u>C.3</u>	1 my 2 and	00	-//-

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.